We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Differentiates Parkinson's from Similar Diseases

By LabMedica International staff writers
Posted on 22 Feb 2017
Print article
Image: The Simoa HD-1 ultrasensitive immunoassay platform (Photo courtesy of Quanterix).
Image: The Simoa HD-1 ultrasensitive immunoassay platform (Photo courtesy of Quanterix).
In early stages of disease, it can be difficult to differentiate between Parkinson's disease and atypical parkinsonism disorders (APDs) like multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, because symptoms can overlap.

A simple blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson's disease or another atypical Parkinsonism disorder as identifying these diseases early is important because expectations concerning progression and potential benefit from treatment differ dramatically between Parkinson's and APDs.

Scientists at Lund University and their colleagues examined 504 people from three study groups. Two groups, one in England and one in Sweden, had healthy people and people who had been living with Parkinson's or APDs for an average of four to six years. The third group was comprised of people who had been living with the diseases for three years or less. In all, there were 244 people with Parkinson's, 88 with multiple system atrophy, 70 with progressive supranuclear palsy, 23 with corticobasal degeneration and 79 people who served as healthy controls.

The investigators used a sensitive sandwich method, the Nflight enzyme-linked immunosorbent assay (ELISA) kit to measure cerebrospinal fluid (CSF) neurofilament light chain protein (NfL). NfL concentrations in blood were measured using the monoclonal antibodies and calibrator from the NfL assay, transferred onto the Simoa platform using an in-house kit.

The team found the blood test was just as accurate as a spinal fluid test at diagnosing whether someone had Parkinson's or an APD, in both early stages of disease and in those who had been living with the diseases longer. The nerve protein levels were higher in people with APDs and lower in those with Parkinson's disease and those who were healthy. In the Swedish group, the protein levels averaged around 10 pg/mL. People with multiple system atrophy had levels averaging around 20 pg/mL; those with progressive supranuclear palsy averaged around 25 pg/mL; and those with corticobasal degeneration averaged around 27 pg/mL.

Oskar Hansson, MD, PhD, the lead author of the study said, “We have found that concentrations of a nerve protein in the blood can discriminate between these diseases as accurately as concentrations of that same protein in spinal fluid. Lower concentrations of the nerve protein in the blood of those with Parkinson's may be due to less damage to nerve fibers compared to those with atypical Parkinsonism disorders.” The study was published on February 8, 2017, in the journal Neurology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.